Molecular epidemiology of malaria in Yaounde, Cameroon I. Analysis of point mutations in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum

American Journal of Tropical Medicine and Hygiene

Volumn 58, Issue 3, 1998, Pages 369-373

  Basco, Leonardo K ^a   Ringwald, Pascal ^a  

^a Laboratoire de Recherche sur le Paludisme Yaounde   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ASPARAGINE; CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; PROGUANIL; PYRIMETHAMINE; PYRONARIDINE; SERINE; THYMIDYLATE SYNTHASE;

ADULT; ARTICLE; CAMEROON; CLINICAL TRIAL; CODON; DRUG SENSITIVITY; GENE; HUMAN; HUMAN CELL; MALARIA FALCIPARUM; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0031924182     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1998.58.369     Document Type: Article

References (30)

1. Manga L, Fondjo E, Carnevale P, Robert V, 1993. Importance of low dispersion of Anopheles gambiae (Diptera: Culicidae) on malaria transmission in hilly towns in south Cameroon. J Med Entomol 30: 936-938.
2. Ringwald P, Bickii J, Basco LK, 1996. In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg 55: 254-258.
3. Wernsdorfer, WH, 1994. Epidemiology of drug resistance in malaria. Acta Trop 56: 143-156.
4. Hyde JE, 1990. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol Ther 48: 45-59.
5. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ, 1988. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 85: 9109-9113.
6. Peterson DS, Walliker D, Wellems TE, 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85: 9114-9118.
7. Zolg JW, Plitt JR, Chen GX, Palmer S, 1989. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol 36: 253-262.
8. Basco LK, Eldin de Pecoulas P, Wilson CM, Le Bras J, Mazabraud A, 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 69: 135-138.
9. Foote SJ, Galatas D, Cowman AF, 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 87: 3014-3017.
10. Peterson DS, Milhous WK, Wellems TE, 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 87: 3018-3022.
11. Eldin de Pecoulas P, Basco LK, Abdallah B, Dje MK, Le Bras J, Mazabraud A, 1995. Plasmodium falciparum: detection of antifolate resistance by mutation-specific restriction enzyme digestion. Exp Parasitol 80: 483-487.
12. Eldin de Pecoulas P, Basco LK, Le Bras J, Mazabraud A, 1996. Association between antifol resistance in vitro and DHFR point mutation in Plasmodium falciparum isolates. Trans R Soc Trop Med Hyg 90: 181-182.
13. Ringwald P, Bickii J, Basco LK, 1996. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa, Lancet 347: 24-28.
14. Bzik DJ, Li WB, Horii T, Inselburg J, 1987. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci USA 84: 8360-8364.
15. Snewin VA, England SM, Sims PFG, Hyde JE, 1989. Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. Gene 76: 41-52.
16. Curtis J, Duraisingh MT, Trigg JK, Mbwana H, Warhurst DC, Curtis CF, 1996. Direct evidence that asparagine at position 108 of the Plasmodium falciparum dihydrofolate reductase is involved in resistance to antifolate drugs in Tanzania. Trans R Soc Trop Med Hyg 90: 678-680.
17. Zindrou S, Le DD, Pham TX, Nguyen PD, Nguyen DS, Skold O, Swedberg G, 1996. Rapid detection of pyrimethamine susceptibility of Plasmodium falciparum by restriction endonuclease digestion of the dihydrofolate reductase gene. Am J Trop Med Hyg 54: 185-188.
18. Mount DL, Nahlen BL, Patchen LC, Churchill FC, 1989. Adaptations of the Saker-Solomons test: simple, reliable colorimetric field assays for chloroquine and its metabolites in urine. Bull World Health Organ 67: 295-300.
19. Basco LK, Ramiliarisoa O, Le Bras J, 1994. In vitro activity of pyrimethamine, cycloguanil, and other antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 50: 193-199.
20. Reeder JC, Rieckmann KH. Genton B, Lorry K, Wines B, Cowman AF, 1996. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg 55: 209-213.
21. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE, 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52: 565-568.
22. Hengy C, Eberle F, Gazin P, Kouka-Bemba D, Gelas H, Jambou R, 1990. Acces palustres simples en zone de haut niveau de resistance a la chloroquine. 3. Emploi de traitements de deuxieme intention, par voie orale. Bull Soc Pathol Exot 83: 61-65.
23. Charmot G, Simon F, Le Bras J, 1987. Deux cas de paludisme a Plasmodium falciparum multiresistant contracte a Douala avec presentation clinique atypique. Bull Soc Pathol Exot 80: 447-451.
24. Ekanem OJ, Weisfeld JS, Salako LA, Nahlen BL, Ezedinachi ENU, Walker O, Breman JG, Laoye OJ, Hedberg K, 1990. Sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine/pyrimethamine in Nigerian children. Bull World Health Organ 68: 45-52.
25. Metzger W, Mordmuller B, Graninger W, Bienzle U, Kremsner PG, 1995. Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. J Antimicrob Chemother 36: 723-728.
26. Chulay JD, Watkins WM, Sixsmith DJ, 1984. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg 33: 325-330.
27. Basco LK, Ringwald P, 1998. Molecular epidemiology of malaria in Yaounde, Cameroon. II. Baseline frequency of point mutations in the dihydropteroate synthase gene of Plasmodium falciparum. Am J Trop Med Hyg 58: 374-377.
28. Basco LK, Eidin de Pecoulas P, Le Bras J, Wilson CM, 1996. Plasmodium falciparum: molecular characterization of multidrug-resistant Cambodian isolates. Exp Parasitol 82: 97-103.
29. Peterson DS, Di Santi SM, Povoa M, Calvosa VS, do Rosario VE, Wellems TE, 1991. Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon. Am J Trop Med Hyg 45: 492-497.
30. Plowe CV, Djimde A, Wellems TE, Diop S, Kouriba B, Doumbo OK, 1996. Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Am J Trop Med Hyg 55: 467-471.